AF
Therapeutic Areas
PMV Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PC14586 (revetrectinib) | Advanced solid tumors with p53 Y220C mutation | Phase 1/2 |
Leadership Team at PMV Pharmaceuticals
DM
David Mack, Ph.D.
Co-founder, President and Chief Executive Officer
DJ
Deepika Jalota
Chief Business Officer
WK
Winston Kung
Chief Financial Officer
KM
Kathleen Mahoney, M.D.
Chief Medical Officer
AL
Arnold Levine, Ph.D.
Co-founder and Chair of Scientific Advisory Board
AG
Andreas G. Bader, Ph.D.
Chief Scientific Officer
CP
Carol Prives, Ph.D.
Scientific Advisory Board Member